$35.37
0.120.34%
Últ. Act.: Oct 30, 7:40 PM
Indivior Pharmaceuticals (INDV) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
Indivior Pharmaceuticals (INDV) publicó su última previsión de octubre 29, 2026 para fiscal year 2026. La compañía estimó ingresos en un rango de $1.29B - $1.36B para el período.
En comparación con la previsión anterior, Indivior Pharmaceuticals mantenido redujo su previsión de ingresos desde un rango anterior de $1.29B - $1.36B.
Indivior Pharmaceuticals ha emitido 18 actualizaciones de orientación entre el octubre 23, 2023 y el octubre 29, 2026. During this period, the company raised its outlook 5 times and lowered it 6 times, providing investors with insight into management's evolving expectations.
| Metric | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $1.08 | $0.92 | $0.66 | $0.66 |
| Actual | $1.32 | $1.15 | $0.96 | $0.82 |
| Surprise | +22.2% | +25.0% | +45.5% | +24.2% |
| Revenue | ||||
| Estimate | $328.8M | $306.8M | $272.0M | $305.5M |
| Actual | $356.0M | $343.0M | $317.0M | $358.0M |
| Surprise | +8.27% | +11.8% | +16.5% | +17.2% |
| Metric | Q4 '26E | Q1 '27E |
|---|---|---|
| Earnings Per Share (Non-GAAP) | ||
| Consensus | $1.19 | $0.95 |
| Revenue | ||
| Consensus | $336.6M | $328.0M |
| Trimestre Fiscal | Fecha reportada | EPS real | EPS estimado | Sorpresa % |
|---|---|---|---|---|
| Q3 | Oct 29, 2026 | $1.32 | $1.08 | 22.2 % |
| Q2 | Aug 3, 2026 | $1.15 | $0.92 | 25.0 % |
| Q1 | Apr 30, 2026 | $0.96 | $0.66 | 45.5 % |
| Q4 | Feb 26, 2026 | $0.82 | $0.66 | 24.2 % |
| Trimestre Fiscal | Fecha reportada | Ingresos reales | Ingresos estimados | Sorpresa % |
|---|---|---|---|---|
| Q3 | Oct 29, 2026 | $356.00M | $328.82M | 8.27 % |
| Q2 | Aug 3, 2026 | $343.00M | $306.84M | 11.8 % |
| Q1 | Apr 30, 2026 | $317.00M | $272.00M | 16.5 % |
| Q4 | Feb 26, 2026 | $358.00M | $305.46M | 17.2 % |